BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32461304)

  • 21. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
    Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
    DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and management of neuroendocrine prostate cancer.
    de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
    Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
    Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
    Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
    Korsen JA; Kalidindi TM; Khitrov S; Samuels ZV; Chakraborty G; Gutierrez JA; Poirier JT; Rudin CM; Chen Y; Morris MJ; Pillarsetty N; Lewis JS
    J Nucl Med; 2022 Sep; 63(9):1401-1407. PubMed ID: 35058323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neural Transcription Factors in Disease Progression.
    Thaper D; Vahid S; Zoubeidi A
    Adv Exp Med Biol; 2019; 1210():437-462. PubMed ID: 31900920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
    J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
    Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
    Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
    Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.
    Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Turpin A; Delliaux C; Parent P; Chevalier H; Escudero-Iriarte C; Bonardi F; Vanpouille N; Flourens A; Querol J; Carnot A; Leroy X; Herranz N; Lanel T; Villers A; Olivier J; Touzet H; de Launoit Y; Tian TV; Duterque-Coquillaud M
    Br J Cancer; 2023 Dec; 129(12):1903-1914. PubMed ID: 37875732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
    Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
    Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
    Corella AN; Cabiliza Ordonio MVA; Coleman I; Lucas JM; Kaipainen A; Nguyen HM; Sondheim D; Brown LG; True LD; Lee JK; MacPherson D; Nghiem P; Gulati R; Morrissey C; Corey E; Nelson PS
    Clin Cancer Res; 2020 Apr; 26(7):1667-1677. PubMed ID: 31806643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.